An evaluation of the CTLA-4 expression revealed that this co-inhibitory molecule was elevated in T cells in patients with high-risk ALL (108); in addition, CTLA-4 solubility was significantly elevated in 70% of B-ALL pediatric patients with active disease (109). This evidence concerns the gene CTLA4 and acute lymphoblastic leukemia.